Digital Patient Decision Aid for Antiobesity Medications: Mixed Methods Study of Human-Centered Design and Usability Evaluation
-
By
-
Li-Jen Wang
-
Yi-Jen Wang
-
Yu-Lun Cheng
-
Wen-Liang Fang
-
Weu Wang
-
Meng-Cong Zheng
-
May 15, 2026
-
Clinical Scorecard: Patient-Centered Digital Decision Support for Antiobesity Treatments: A Mixed Methods Evaluation of Design and Usability
At a Glance
| Category | Detail |
|---|
| Condition | Obesity |
| Key Mechanisms | Patient decision aids (PDAs) enhance shared decision-making by presenting treatment options and their risks and benefits. |
| Target Population | Adults considering antiobesity medications (AOMs) in Taiwan. |
| Care Setting | Clinical settings in Taiwan, specifically in weight management. |
Key Highlights
- Obesity prevalence in Taiwan increased from 32.7% to 50.8% from 1993-2022.
- Antiobesity medications are effective but require preference-sensitive decision-making.
- Existing PDAs primarily target surgical options, leaving a gap for AOM decision support.
- OptiWeight, a digital PDA, was developed to assist adults in selecting AOMs.
- User-centered design principles guided the development and refinement of OptiWeight.
Guideline-Based Recommendations
Diagnosis
- Assess obesity prevalence and its impact on health outcomes.
Management
- Utilize patient decision aids to facilitate informed choices among AOMs.
Monitoring & Follow-up
- Evaluate patient understanding and satisfaction with treatment options.
Risks
- Consider potential side effects and individual patient preferences in treatment selection.
Patient & Prescribing Data
Adults with obesity considering medication therapy.
AOM selection should align with patient values and preferences.
Clinical Best Practices
- Implement shared decision-making in obesity treatment.
- Utilize PDAs to enhance patient knowledge and reduce decisional conflict.
- Ensure PDAs are tailored to the local context and patient needs.
Related Resources & Content
